Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High‐Risk Muscle‐Invasive Urothelial Carcinoma: A Real‐World Study
Tisle+GC is a promising adjuvant treatment for high-risk MIUC, offering improved survival outcomes with a manageable safety profile. Further prospective studies are needed to confirm these results and establish the long-term benefits of this combination therapy.
Authors
- Kai Yao (ORCID: https://orcid.org/0000-0002-2589-3058)
- Xingliang Tan (ORCID: https://orcid.org/0000-0002-4015-4982)
- Qianghua Zhou (ORCID: https://orcid.org/0000-0002-6709-2291)
- Kaihua Zhong (ORCID: https://orcid.org/0000-0002-7926-9883)
- Lijuan Jiang (ORCID: https://orcid.org/0000-0003-2654-7920)
- Zhiming Wu (ORCID: https://orcid.org/0009-0009-2686-2200)
- Yanjun Wang (ORCID: https://orcid.org/0000-0001-6121-8706)
Institutions
- Sun Yat-sen University (CN)
- Meizhou City People's Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/cam4.70661
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Sun Yat-sen University
- Sun Yat-sen University Cancer Center